NEW YORK and MAINZ, GERMANY, November 18, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 28 days after the first dose, 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.

Original post:
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (OTCQB: BTTR) (the “Company” or “Better Choice”), an animal health and wellness company, today reported its financial results for the third quarter ended September 30, 2020.

Continue reading here:
Better Choice Company Reports Third Quarter and Year-to-Date 2020 Financial Results

New York City, Nov. 18, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotech company focused on development and commercialization of interferon (IFN) based therapeutics, recently provided a clinical and regulatory update for its AP-003 COVID-19 clinical trials using inhaled interferon alpha 2b.  While recent advancements in vaccines may seem to provide a glimmer of hope for bringing the pandemic to a close, it remains to be seen how safe and effective they will be, and for how long. The importance of life-saving COVID-19 therapeutics is as great ever, and the support for the Company’s use of interferon as a therapeutic for COVID-19 is compelling.

Here is the original post:
What do the Pfizer Vaccine and BetterLife Pharma have in common?

The Company takes first step in its expansion with the addition of a 300,000 sq. ft. facility within Monterey County The Company takes first step in its expansion with the addition of a 300,000 sq. ft. facility within Monterey County

See the article here:
Indus Holdings, Inc. Announces Preliminary Expansion Plans

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

View original post here:
Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

PRINCETON, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced the appointment of Douglas W. Losordo, MD, FACC, FAHA to the newly created position of Chief Medical Officer, effective immediately. Dr. Losordo, who will report directly to CEO Thijs Spoor, will lead all global clinical development and regulatory initiatives for the Company. Dr. Losordo is an accomplished physician and healthcare executive with more than 20 years of academic research, clinical and corporate experience.

See the original post here:
KBP Biosciences Appoints Douglas Losordo Chief Medical Officer

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of NPM1-mutated acute myeloid leukemia

More here:
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *

Follow this link:
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte’s 2020 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress’ 874 percent revenue growth based on the increase in net product sales from 2016 to 2019 secured its spot in the rankings.

Read the original here:
Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row

-- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL’s commitment to advancing the clinical and scientific platform supporting Upneeq -- -- Addition of Dr. Raymond Douglas, M.D., PhD, further enhances RVL’s commitment to advancing the clinical and scientific platform supporting Upneeq --

Go here to read the rest:
RVL Pharmaceuticals, Inc. Strengthens Leadership Team as Commercial Launch of Upneeq® Expands

BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has decided to cancel the Antimicrobial Drug Advisory Committee meeting tentatively scheduled for January 14, 2021 to discuss the New Drug Application (NDA) for Defencath®. When the FDA accepted for filing the Company’s submitted NDA and granted priority review, it set a Prescription Drug User Fee Act (PDUFA) date of February 28, 2021 for the completion of its review for approval of the NDA. The Agency noted that it was planning to hold an advisory committee meeting to discuss the application for Defencath to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI) and that it had not identified any potential review issues at that time. CorMedix has been notified that based on the Agency’s ongoing dialogue with the Company, discussion at an advisory committee is not needed, and it will continue to work on the application with CorMedix during the remainder of the review cycle.

Read the original:
CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not Needed

NEW YORK and CUPERTINO, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that an Extraordinary General Meeting of Shareholders of Tenzing (the "Shareholder Meeting") to approve the pending business combination between Tenzing and Reviva (the “Business Combination”) is scheduled to be held on Tuesday, December 8, 2020, at 9:00 a.m., Eastern time. Due to COVID-19 restrictions on in-person meetings, the Shareholder Meeting will be completely virtual and conducted via live webcast.

View original post here:
Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Shareholder Meeting Date to Approve the Business Combination

MIRAMAR, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO).

The rest is here:
Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform

Last Patient/Last Visit completed on November 13th enabling full clinical database lock

Read the rest here:
AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 18, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive clinical proof of concept data from its lab-based rapid SARS-CoV-2 3CL protease diagnostic assay in collaboration with its COVID Antigen Test Killer LLC joint venture partner NLC Pharma. The data generated by NLC Pharma in Israel produced 100% sensitivity and 100% specificity in PCR-confirmed positive and negative COVID-19 patient samples. The team is now gathering additional clinical data to submit an emergency use authorization (EUA) to the United States Food & Drug Administration ( FDA) for its lab-based test to be distributed through Todos’ existing lab distribution channels.  Todos is evaluating the best option for the commercialization of its rapid point-of-care version of the 3CL protease assay for the screening and diagnosis of symptomatic and asymptomatic COVID-19 carriers, based on recent updated guidance from the FDA for COVID-19 diagnostic point of care tests.

Original post:
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay

These therapeutics will benefit the treatment of multiple diseases including autoimmune diseases, acute inflammation and cancer These therapeutics will benefit the treatment of multiple diseases including autoimmune diseases, acute inflammation and cancer

Continue reading here:
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001

A scientific review article “Toll-Like Receptor 9 Agonists in Cancer”, written by Dr Davar Diwakar et al, a prominent immune-oncology research group in Pittsburgh (US), was recently published in the  OncoTargets and Therapy journal discussing and reviewing key players in preclinical studies and ongoing clinical trials of TLR9 agonists. TLR9 is one of the most promising targets for increasing the response and reversing the resistance to current cancer immunotherapies.

The rest is here:
A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in...

WILLIAMSVILLE, N.Y., Nov. 18, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that Chief Executive Officer, James A. Mish, will speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 11:50 a.m. EST. The virtual conference is a forum for objective first-hand updates on both marketed and emerging products across the spectrum of the cannabis industry focusing on consumer, technology, and healthcare.

See the rest here:
22nd Century Group CEO James A. Mish to Speak at Cowen 2020 Boston Cannabis Conference

NEW YORK, NY and SAN DIEGO, CA, Nov. 18, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- As previously announced, during April 2020, Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc. (“Aegea”) have entered into a collaboration agreement to develop COVID-19 (novel coronavirus) assays. Aegea has made substantial progress in designing and developing two different, next generation assays for SARS-CoV-2.

Read the original post:
Tauriga Sciences Inc. Updates Shareholders on Progress Pursuant to the Collaboration Agreement with Aegea Biotechnologies Inc. for New COVID-19...

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

Spinal Cord Trauma Treatment Market: Global Industry Analysis 2012 2016 and Forecast 2017 2025is the recent report of Persistence Market Research that throws light on the overall market scenario during the period of eight years, i.e. 2017-2025. According to this report, Globalspinal cord trauma treatment marketis expected to witness significant growth during the forecast period.

This growth is expected to be primarily driven by increasing incidence of spinal cord trauma, and increasing government support to reduce the burden of spinal cord injuries. Additionally, development of nerve cells growth therapy is expected to boost the market in near future.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17353

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17353

The global market for spinal cord trauma treatment is is estimated to be valued at US$ 2,276.3 Mn in terms of value by the end of 2017. The global spinal cord trauma treatment market is expected to expand at a CAGR of 3.7% over the forecast period to reach a value of US$ 3,036.2 Mn by 2025end.

Global Spinal Cord Trauma Treatment Market: Trends

Global Spinal Cord Trauma Treatment Market: Forecast by End User

On the basis of end user, the global spinal cord trauma treatment market is segmented into hospitals and trauma centers. Hospitals segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period.

Hospitals and trauma centers segments are expected to approximately similar attractive index. Hospitals segment accounted for 53.2% value share in 2017 and is projected to account for 52.5% share by 2025 end.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17353

Global Spinal Cord Trauma Treatment Market: Forecast by Injury Type

On the basis of injury type, the global spinal cord trauma treatment market is segmented into complete spinal cord injuries and partial spinal cord injuries.

Partial spinal cord trauma treatment segment is expected to show better growth than the completed spinal cord treatment segment due to higher growth in the incidence rate of partial spinal cord trauma than the complete spinal cord trauma. With US$ 1,870.3 Mn market value in 2025, this segment is likely to expand at CAGR 3.8% throughout the projected period.

Global Spinal Cord Trauma Treatment Market: Forecast by Treatment Type

On the basis of treatment type, the global spinal cord trauma treatment market is segmented into corticosteroid, surgery, and spinal traction segments.

Surgery segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Surgery segment is the most attractive segment, with attractiveness index of 2.6 over the forecast period.

Global Spinal Cord Trauma Treatment Market: Forecast by Region

This market is segmented into five regions such as North America, Latin America, Europe, APAC and MEA. Asia-Pacific account for the largest market share in the global spinal cord trauma treatment market.

Large patient population due to the high rate of road accidents and crime is making the Asia Pacific region most attractive market for spinal cord trauma treatment. On the other hand, MEA and Latin America is expected to be the least attractive market for spinal cord trauma treatment, with attractiveness index of 0.3 and 0.5 respectively over the forecast period.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

More here:
The Spinal Cord Trauma Treatment Market To Walk The Path Of Double Digit CAGR Of 3.7% - KYT24